Pharmacologic class (EPC) · 5 drug pages

Echinocandin antifungal: adverse event reports filed with FDA

7,377 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

7,377
reports across the class: 0% of all reports; 360
reports, 12 months to June 2026: 421 in the 12 months before; 87.9%
marked serious by the reporter: 57.4% across all reports; 5
drugs with a page: brand and generic names counted separately

Echinocandin antifungal is a pharmacologic class (an FDA Established Pharmacologic Class) with 5 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 7,377 adverse event reports received by FDA, 0% of the database, from January 2004 to June 2026.

360 reports arrived in the 12 months to June 2026, down 14% from 421 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 87.9% of the class's reports are marked serious, 36.7% record death among the outcomes and 36.9% record hospitalisation, as reported.

Across the class the reactions recorded most often are drug ineffective (20.7%), off label use (12.8%) and death (5.7%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
CancidasCaspofungin acetate	brand	2,296	18	90.9%	Drug ineffective
Micafungin	generic	1,970	156	97.2%	Drug ineffective
MycamineMicafungin sodium	brand	1,406	15	58.9%	Off label use
Caspofungin acetate	generic	1,011	94	95.3%	Drug ineffective
Anidulafungin	generic	694	77	99.6%	Drug ineffective

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Drug ineffectivethe medicine did not work as expected20.7%1,525
Off label useused for a purpose or in a way not on the label12.8%941
Deaththe patient died; cause not stated by this term5.7%423
Product use in unapproved indicationused for a purpose not on the label5.2%382
Multiple organ dysfunction syndromeseveral organs failing4.5%335
Septic shockshock arising from infection3.9%290
Candida infectionthrush, a yeast infection3.3%241
Drug resistance3%219
Fungal infectiona fungal infection2.9%215
Sepsisa severe body-wide response to infection2.8%210
Pneumonialung infection2.8%207
Renal failurekidney failure2.7%196
Pyrexiafever2.6%195
Condition aggravatedthe condition being treated got worse2.5%183
Neutropenialow neutrophils, a type of white blood cell2.4%178
Acute kidney injurysudden loss of kidney function2.4%175
Respiratory failurethe lungs could not supply enough oxygen2.2%164
Aspergillus infection2%146
Systemic candida1.9%142
Product use issuea problem in how the product was used1.8%131
Bacterial infectiona bacterial infection1.7%127
Bronchopulmonary aspergillosis1.7%126
Diarrhoealoose or frequent stools1.7%125
Febrile neutropeniafever with low white blood cells1.7%122
Toxic epidermal necrolysisa severe skin reaction with peeling1.7%122

Solid bar: share of all class reports. Hollow bar: the median share across the 5 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death36.7%2,704

Life-threatening11%814

Hospitalisation (initial or prolonged)36.9%2,719

Disability1.4%100

Congenital anomaly0.1%9

Other serious52.2%3,854

Not serious12.1%892

Patient age

Under 21.7%123

2 to 115%370

12 to 174.1%302

18 to 4418.7%1,380

45 to 6427.4%2,024

65 to 7413%957

75 and over8.5%626

Age not given21.6%1,595

Who reported

Physician35.6%2,625

Pharmacist6.9%509

Other health professional37.1%2,739

Lawyer0.1%8

Consumer or non-health professional18.1%1,335

Not given2.2%161

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Echinocandin antifungal reports

Which drugs are in the Echinocandin antifungal class on this site?

Cancidas, Micafungin, Mycamine, Caspofungin acetate and Anidulafungin. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

7,377 reports through June 2026, 360 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

drug ineffective (20.7%), off label use (12.8%), death (5.7%), product use in unapproved indication (5.2%) and multiple organ dysfunction syndrome (4.5%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.